Hims Enclomiphene: Program Details, Pricing, and Review

If you searched “hims enclomiphene,” you probably want three things in one place: what the program actually includes, what it costs in real life (not just a headline), and whether it is any good relative to alternatives. This article is structured exactly that way—program details first, pricing second, review third—with numbers tied to Hims’ own marketing disclosures and to T-Compare’s public listing snapshot, plus peer-reviewed context for the medication class.

Part 1 — Program details: what Hims sells under “Testosterone Rx”

Hims groups its low-testosterone telehealth offering under language like “Testosterone Rx” and positions enclomiphene citrate as an oral option intended to stimulate your body’s own testosterone production in appropriate candidates—rather than supplying exogenous testosterone in every pathway. Public pages have described two prescription configurations: enclomiphene-only treatment and a combination product that pairs enclomiphene with tadalafil where a clinician judges both testosterone support and erectile-function help to be appropriate.

The clinical model is telehealth-first: you complete an intake, a licensed provider evaluates whether a prescription is appropriate, and labs are part of eligibility and monitoring in the way Hims frames care (exact kit cadence and pricing should be confirmed at checkout). Hims also publicly states that compounded drug products are not FDA-approved or evaluated by the FDA for safety and effectiveness in the same manner as commercially manufactured drugs—a key informed-consent point for any compounded enclomiphene program.

• Medication class: selective estrogen receptor modulator (SERM) pathway—upstream pituitary/testis signaling rather than direct testosterone replacement in the enclomiphene-only configuration.
• Fertility framing: marketing materials commonly contrast enclomiphene pathways with traditional testosterone replacement when discussing sperm suppression risk—your goals should be reviewed with a clinician.
• Injections: Hims has publicly indicated it does not currently offer testosterone replacement injections through this same funnel—if you need TRT specifically, this may be the wrong program category.

Hims cites peer-reviewed enclomiphene development literature on its consumer pages (for example trial work in secondary hypogonadism populations). Those citations support population-level hormone endpoints in study designs—not a promise that your symptoms resolve on a fixed calendar.

Part 2 — Pricing: how “from $99/month” actually behaves

T-Compare’s independent listing for Hims currently shows a starting price of about $99 per month derived from publicly available program marketing—use that figure as an anchor, not a guaranteed invoice. Hims has advertised multi-month plans (commonly discussed in 3-, 5-, and 10-month horizons on its testosterone pages), which means the lowest monthly rate is often tied to longer upfront commitment rather than month-to-month flexibility.

Hims’ own consumer pages (including Good Health by Hims pricing explainers and hims.com/testosterone) have published plan-dependent monthly equivalents when paying upfront: about $199/month on a three-month plan, about $139/month on a five-month plan, and about $99/month on a 10-month plan for enclomiphene-based Testosterone Rx, with an initial at-home lab kit commonly listed around $94 and language that the kit fee may be credited toward treatment if you are eligible. Third-party summaries repeat these figures, but your invoice is authoritative—verify at checkout.

• Baseline row for comparisons: ~$99/mo starting framing vs T-Compare’s other enclomiphene listings (for example ~$69/mo TTime, ~$100/mo Maximus Tribe snapshot, ~$149/mo Hone Health)—all subject to change.
• Add-ons that commonly move the true monthly cost: at-home or local lab panels, repeat labs, shipping, taxes, and any non-medication services billed separately.
• Promotions: seasonal discounts can temporarily invert the ranking—rebuild the spreadsheet at purchase time.

Before you pay, export Hims’ checkout breakdown into three lines—medication, labs, shipping—and compare that 90-day total to other providers using the same three lines. Headline “per month” rates are easy; all-in quarterly totals are harder to fudge.

Part 3 — Review: an editorial verdict without fake star ratings

T-Compare does not fabricate user reviews or aggregate unverified app-store ratings. Instead, below is a transparent scorecard of tradeoffs informed by program structure, pricing position, and regulatory disclosures.

Strengths (why shoppers shortlist Hims)

• National telehealth brand with standardized onboarding language—useful if you want a predictable funnel and clear compounded-product disclosures on marketing pages.
• Listed mid-pack pricing on T-Compare: cheaper than some premium-positioned peers at published starting rates, more expensive than the lowest advertised enclomiphene entry points.
• Clinical citations on consumer pages—when read carefully, they can help you ask better questions about trial designs versus marketing headlines.

Limitations (what should slow you down)

• Compounded enclomiphene is not an FDA-approved finished drug product in the same sense as many legacy testosterone formulations—monitoring and pharmacy sourcing matter.
• Not all states or situations qualify; online care rules and clinician judgment still gate access.
• Symptom relief timelines vary: hormone movement and perceived energy/libido changes are not identical timelines.

Who it fits on paper (education only)

On paper, Hims’ enclomiphene pathway is aimed at men whose clinicians consider secondary hypogonadism–style physiology and who want an oral, fertility-aware framing rather than jumping straight to exogenous testosterone. Only labs and history determine whether that statement applies to you.

Use T-Compare’s dedicated Hims provider page for side-by-side fields, then confirm every material term on hims.com/testosterone before you subscribe.